scholarly journals The Current Landscape of Oncolytic Herpes Simplex Viruses as Novel Therapies for Brain Malignancies

Viruses ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 1158
Author(s):  
Joshua D. Bernstock ◽  
Samantha E. Hoffman ◽  
Jason A. Chen ◽  
Saksham Gupta ◽  
Ari D. Kappel ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Brain Tumors ◽  
Therapeutic Strategies ◽  
High Grade ◽  
Novel Therapies ◽  
Herpes Viruses ◽  
Significant Morbidity ◽  
Herpes Simplex Viruses ◽  
Novel Therapeutic Strategies ◽  
Novel Therapeutic

Despite advances in surgical resection and chemoradiation, high-grade brain tumors continue to be associated with significant morbidity/mortality. Novel therapeutic strategies and approaches are, therefore, desperately needed for patients and their families. Given the success experienced in treating multiple other forms of cancer, immunotherapy and, in particular, immunovirotherapy are at the forefront amongst novel therapeutic strategies that are currently under investigation for incurable brain tumors. Accordingly, herein, we provide a focused mini review of pertinent oncolytic herpes viruses (oHSV) that are being investigated in clinical trials.

Novel therapeutic strategies

2018 ◽  
Author(s):  
Jim Cassidy ◽  
Donald Bissett ◽  
Roy A. J. Spence OBE ◽  
Miranda Payne ◽  
Gareth Morris-Stiff
Keyword(s):  
Clinical Trials ◽  
Research And Development ◽  
Combined Modality Therapy ◽  
Operative Therapy ◽  
Therapeutic Strategies ◽  
Combined Modality ◽  
Novel Therapeutic Strategies ◽  
Chemotherapy Agents ◽  
Novel Therapeutic

Describes 4 areas of research and development in oncology. Discusses design of clinical trials for chemotherapy agents, newer modalities of radiotherapy including targeted and intra-operative therapy. Explians rationale for combined modality therapy

scholarly journals Biological intratumoral therapy for the high-grade glioma part I: intratumoral delivery and immunotoxins

CNS Oncology ◽  
2019 ◽  
Vol 8 (3) ◽  
pp. CNS38 ◽  
Author(s):  
Joshua Loya ◽  
Charlie Zhang ◽  
Emily Cox ◽  
Achal S Achrol ◽  
Santosh Kesari
Keyword(s):  
Translational Research ◽  
Standard Of Care ◽  
High Grade Glioma ◽  
Therapeutic Strategies ◽  
High Grade ◽  
Major Focus ◽  
Microsurgical Resection ◽  
Intratumoral Delivery ◽  
Novel Therapeutic Strategies ◽  
Novel Therapeutic

Management of high-grade gliomas remains a complex challenge. Standard of care consists of microsurgical resection, chemotherapy and radiation, but despite these aggressive multimodality therapies the overall prognosis remains poor. A major focus of ongoing translational research studies is to develop novel therapeutic strategies that can maximize tumor cell eradication while minimizing collateral side effects. Particularly, biological intratumoral therapies have been the focus of new translational research efforts due to their inherent potential to be both dynamically adaptive and target specific. This two-part review will provide an overview of biological intratumoral therapies and summarize key advances and remaining challenges in intratumoral biological therapies for high-grade glioma. Part I focuses on discussion of the concepts of intratumoral delivery and immunotoxin therapies.

scholarly journals Nutrients in Alzheimer’s Disease: The Interaction of Diet, Drugs and Disease

2019 ◽  
Vol 46 (1) ◽  
pp. 23-34 ◽  
Author(s):  
S. Imindu Liyanage ◽  
Prachi Vilekar ◽  
Donald F. Weaver
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Trials ◽  
Therapeutic Strategies ◽  
Protective Agent ◽  
Dietary Preferences ◽  
Novel Therapeutic Strategies ◽  
The Impact ◽  
Potential Therapeutics ◽  
Novel Therapeutic

AbstractIn recent decades, clinical trials in Alzheimer’s disease (AD) have failed at an unprecedented rate. The etiology of AD has since come under renewed scrutiny, both to elucidate the underlying pathologies and to identify novel therapeutic strategies. Here, diet has emerged as a potential causative/protective agent. A variety of nutrients, including lipids, minerals, vitamins, antioxidants and sugars as well as broader dietary patterns and microbiotal interactions have demonstrated associations with AD. Although clinical trials have yet to definitively implicate any singular dietary element as therapeutic or causative, it is apparent that dietary preferences, likely in complex synergies, may influence the risk, onset and course of AD. This review catalogs the impact of major dietary elements on AD. It further examines an unexplored reciprocal association where AD may modulate diet, as well as how potential therapeutics may complicate these interactions. In doing so, we observe diet may have profound effects on the outcome of a clinical trial, either as a confounder of a drug/disease interaction or as a generally disruptive covariate. We therefore conclude that future clinical trials in AD should endeavor to control for diet, either in study design or subsequent analyses.

scholarly journals TMOD-29. ESTABLISHMENT OF PATIENT-DERIVED XENOGRAFTS FROM RARE PRIMARY BRAIN TUMORS

2020 ◽  
Vol 22 (Supplement_2) ◽  
pp. ii234-ii234
Author(s):  
Noriyuki Kijima ◽  
Yoshikazu Nakajima ◽  
Daisuke Kanematsu ◽  
Tomoko Shofuda ◽  
Yuichiro Higuchi ◽  
...  
Keyword(s):  
Brain Tumors ◽  
Translational Research ◽  
Single Cells ◽  
Molecular Classification ◽  
Therapeutic Strategies ◽  
Molecular Characteristics ◽  
Preclinical Development ◽  
Primary Brain Tumors ◽  
Novel Therapeutic Strategies ◽  
Novel Therapeutic

Abstract Patient derived xenografts are essential tools for translational research and preclinical development of novel therapeutic strategies of primary brain tumors. Recent advances in genomics of primary brain tumors revealed molecular classification of primary brain tumors, thus establishment of patient derived xenografts from each subtype of primary brain tumors is urgently needed. However, currently available patient derived xenografts are limited and are from specific subtype of primary brain tumors such as glioblastoma IDH wild type. In this study, we aim to establish patient derived xenografts from primary brain tumors with various molecular characteristics, especially rare primary brain tumors. We got primary brain tumor tissues from patients, dissociated those tissue into single cells, and orthotopically injected those cells into NOD/Shi-scid IL2Rγ KO mouse. We successfully established rare patient-derived xenografts from atypical teratoid rhabdoid tumor and CNS Ewing sarcoma family tumor with CIC alteration, which is recently described as new entity of primitive neuroectodermal tumors of the CNS. We also analyzed histopathological characteristics of these xenografts and found that each xenograft well recapitulated histopathological features of original patients’ resected tumors. These xenografts have advantages for translational research and preclinical development of novel therapeutic strategies for rare primary brain tumors. In addition, further efforts are needed to establish other types of rare primary brain tumors.

Sign in / Sign up

Export Citation Format

Share Document